New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions.
For at least 100 years, immunologists have proposed activating the immune system to specifically target and eradicate autologous tumor cells. The idea that tumor cells can be recognized as foreign to the host's immune system is an essential concept of tumor immunology that was first postulated by Paul Ehrlich at the turn of the century. Anecdotal reports of spontaneous tumor regression have been presumed to be immunologically mediated. With the advent of molecular gene transfer techniques and increased knowledge of the regulation of the immune response, effective methods for harnessing the immune system as a therapeutic agent are finally being realized. Current results of clinical immune/gene therapy protocols will be reviewed with consideration towards the concept of cancer prevention.
Pantuck
A J
AJ
UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-1738 , USA.
Zisman
A
A
Henderson
D
D
Wilson
D
D
Schreiber
A
A
Belldegrun
A
A
D017321:Clinical Trials, Phase I as Topic; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics / Q000627:therapeutic use*; D008297:Male; D018396:Mucin-1 / Q000235:genetics / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy
D007376:Interleukin-2; D018396:Mucin-1